A Study of the Effects of Oxytocin in Adults With Obesity and Binge-eating Disorder

Eligibility Criteria

• * Males and females, 18-45 years old
• * BMI 30-50 kg/m2
• * BED as assessed by Structured Clinical Interview for DSM-5 Disorders (SCID-5-RV)
• * Substance use disorder active within the last 6 months, or clinical suspicion of ongoing substance use disorder at the discretion of the study clinician at the time of screening based on history and/or laboratory results
• * Medication changes within 4 weeks of baseline visit
• * Use of prescription or over-the-counter drugs or dietary/herbal supplements for weight loss (e.g., lorcaserin, phentermine, topiramate, liraglutide). Metformin will be allowed if participants are on a stable dose with stable weight for at least 3 months
• * History of any of the following medical conditions: inflammatory bowel disease; bariatric surgery (except for those participants with a history of laparoscopic adjustable gastric band surgery); epilepsy; untreated thyroid disease
• * History of known cardiovascular disease, including coronary artery disease, heart failure, reduced ejection fraction, hypertrophic cardiomyopathy, ventricular arrhythmias, or prolonged QT
• * Hematocrit \>2% below normal
• * Hemoglobin A1c \>8%
• * ALT or AST \>2.5 times upper limit of normal
• * Glomerular filtration rate \< 60 mL/min
• * Hyponatremia
• * Pregnancy or breastfeeding
• * Unwilling to use a medically acceptable form of contraception throughout the study period (female of child-bearing potential only)
• * History of psychosis or active suicidality as assessed by the SCID-5-RV
• * Weight change \>5 kg within 3 months prior to randomization
• * Current smoking or tobacco use
• * Participation in any clinical study involving an investigational drug, device, or biologic within 1 month of randomization
• * Any significant illness, condition, or medication that the Investigator determines could interfere with study participation and impact data collection or patient safety